[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334495-105":59,"doc-detail-334495-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dars-as1-a-vital-oncogenic-lncrna-regulator-with-potential-for-cancer-prognosis-and-therapy-review","DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy - Review","","DARS-AS1, short for Aspartyl-tRNA synthetase antisense RNA 1, is a key lncRNA in cancers, showing recurrent upregulation across multiple tumor types and acting predominantly as an oncogenic driver. Aberrant DARS-AS1 expression has prompted extensive research to clarify its roles and clinical value. This review summarizes how dysregulated DARS-AS1 expression correlates with poor survival prognoses, drawing on existing literature and pan-cancer analyses from TCGA, and highlights its cancer-specific functions and mechanisms, including ceRNA networks and therapy resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dars-as1-a-vital-oncogenic-lncrna-regulator-with-potential-for-cancer-prognosis-and-therapy-review/334495/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dars-as1-a-vital-oncogenic-lncrna-regulator-with-potential-for-cancer-prognosis-and-therapy-review/334495.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is DARS-AS1 and why is it important in cancer?","Question",{"text":112,"@type":113},"DARS-AS1 (Aspartyl-tRNA synthetase antisense RNA 1) is an antisense lncRNA whose upregulation is recurrent across cancer types. The review describes it as predominantly oncogenic and linked to unfavorable clinicopathological features.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is DARS-AS1 linked to patient prognosis?",{"text":117,"@type":113},"Dysregulated DARS-AS1 expression shows significant correlation with adverse survival prognoses in cancer patients. The review draws on existing literature and pan-cancer analyses from TCGA.",{"name":119,"@type":110,"acceptedAnswer":120},"What topics does the review cover about DARS-AS1?",{"text":121,"@type":113},"It covers molecular mechanisms, ceRNA networks, functional mediators, and signaling pathways. It also summarizes DARS-AS1 involvement in therapy resistance and recent advancements in DARS-AS1-related cancer research.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334495,1790477262,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Ivyspring  \nInternational Publisher  \nInternationalJournal of Medical Sciences  \n2024; 21(3): 571-582. doi: 10.7150/ijms.90611  \nReview  \nDARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy  \nJian Shu1,2\\#, Kejiang Xia3\\#, Hongliang Luo1􀀍, Yang Wang1􀀍  \n1. Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330008, Jiangxi, China.  \n2. Department of Spleen and Stomach Diseases, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang 332000, Jiangxi, China.  \n3. Department of Neurosurgery, Yingtan People's Hospital, Yingtan 335000, Jiangxi, China.  \n\\#These two authors contributed equally to this work.  \n􀀍 Corresponding authors: Hongliang Luo, [email: ndefy13028@ncu.edu.cn](email: ndefy13028@ncu.edu.cn), Tel: +86-13097280001; Yang Wang, email: [iggsnrt@163.com](iggsnrt@163.com), Tel: +86-18070390681.  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [http://ivyspring.com/terms](http://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2023.09.28; Accepted: 2024.01.01; Published: 2024.01.20  \nAbstract  \nDARS-AS1, short for Aspartyl-tRNA synthetase antisense RNA 1, has emerged as a pivotal player in cancers. Upregulation of this lncRNA is a recurrent phenomenon observed across various cancer types, where it predominantly assumes oncogenic roles, exerting influence on multiple facets of tumor cell biology. This aberrant expression of DARS-AS1 has triggered extensive research investigations, aiming to unravel its roles and clinical values in cancer. In this review, we elucidate the significant correlation between dysregulated DARS-AS1 expression and adverse survival prognoses in cancer patients, drawing from existing literature and pan-cancer analyses from The Cancer Genome Atlas (TCGA). Additionally, we provide comprehensive insights into the diverse functions of DARS-AS1 in various cancers. Our review encompasses the elucidation of the molecular mechanisms, ceRNA networks, functional mediators, and signaling pathways, as well as its involvement in therapy resistance, coupled with the latest advancements in DARS-AS1-related cancer research. These recent updates enrich our comprehensive comprehension of the pivotal role played by DARS-AS1 in cancer, thereby paving the way for future applications of DARS-AS1-targeted strategies in tumor prognosis evaluation and therapeutic interventions. This review furnishes valuable insights to advance the ongoing efforts in combating cancer effectively.  \nKeywords: LncRNA, DARS-AS1, Tumor biomarker, Biological Functions, Regulatory mechanism  \nIntroduction  \nInitially, long non-coding RNAs (lncRNAs) were considered as transcriptional noise or \"junk RNA\"since they lacked the functionality of encoding proteins [1-3] . However, as scientific research has advanced, it has become evident that lncRNAs play crucial roles in gene regulation [4-8], involving processes such as transcription, splicing, translation, and chromatin structure modifications. LncRNAshave been found to play key roles in various diseases [9-13], particularly in cancer [14-16] . Moreover, lncRNAs have the potential to serve as valuable biomarkers for progression and prognosis assessment, as well as promising therapeutic targets [17-22] . With the development and widespread use of highthroughput sequencing technologies, an increasing  \nnumber of lncRNAs have been discovered [23-26] .  \nLncRNAs are classified into several categories, such as antisense, sense, intronic, and intergenic, each possessing unique characteristics [27] . Focusing on antisense lncRNAs, these transcripts are uniquely synthesized from the opposite DNA strand of genes that may encode proteins or serve non-coding functions, leading to their critical role in the ons","cbCaiuwd82Y4T3CD","https://ap.wps.com/l/cbCaiuwd82Y4T3CD","pdf",3882660,12,"English","# Introduction\n## Long non-coding RNAs in gene regulation and cancer\n## Antisense lncRNAs and their molecular regulatory mechanisms\n## DARS-AS1: genomic features and oncogenic relevance\n# Abstracted review scope\n## Correlation with survival prognosis and TCGA analyses\n## Functional roles, molecular mechanisms, and therapy resistance","[{\"question\":\"What is DARS-AS1 and why is it important in cancer?\",\"answer\":\"DARS-AS1 (Aspartyl-tRNA synthetase antisense RNA 1) is an antisense lncRNA whose upregulation is recurrent across cancer types. The review describes it as predominantly oncogenic and linked to unfavorable clinicopathological features.\"},{\"question\":\"How is DARS-AS1 linked to patient prognosis?\",\"answer\":\"Dysregulated DARS-AS1 expression shows significant correlation with adverse survival prognoses in cancer patients. The review draws on existing literature and pan-cancer analyses from TCGA.\"},{\"question\":\"What topics does the review cover about DARS-AS1?\",\"answer\":\"It covers molecular mechanisms, ceRNA networks, functional mediators, and signaling pathways. It also summarizes DARS-AS1 involvement in therapy resistance and recent advancements in DARS-AS1-related cancer research.\"}]","DARS-AS1: A Vital Oncogenic LncRNA Regulator with Potential for Cancer Prognosis and Therapy - Review | PDF",1790006887]